Clinical Trial Update: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating regorafenib in combination with paclitaxel for advanced esophagogastric carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Neoplasms
• Stomach Neoplasms

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Regorafenib (regorafenib)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Neoplasms, Stomach Neoplasms | Phase 1, Phase 2 | Status: COMPLETED